San Francisco generative media platform each::labs says it raised a US$7 million seed round co-led by Revo Capital and the EBRD on 18 November 2026, after its annualised revenue run rate passed US$20 million in October.
Boltz raises US$110 million Series A led by Bessemer for biomolecular AI
EditorialBy TrustList Editorial
Boltz, the biomolecular AI company that began as a group of MIT researchers, announced a US$110 million Series A led by Bessemer Venture Partners on 18 November 2026, saying it works with six of the 20 largest drug companies.
- United States
- Machine Learning
- Venture Capital
About Boltz raises US$110 million Series A led by Bessemer for biomolecular AI
Boltz raises US$110 million Series A led by Bessemer for biomolecular AI
18 November 2026: Boltz, which builds AI models that predict and design the structure of biological molecules, has raised US$110 million in a Series A round led by Bessemer Venture Partners. Andrew Hedin and Byron Deeter of Bessemer join the company, which welcomed them in its announcement.
Not yet independently verified. The amount, the investors, the customers and the growth figures come from Boltz's own post of 18 November 2026, read on 19 November. The pharmaceutical partnerships and the 50-fold usage growth are the company's own claims. The post gives no valuation and no head office city. We will update this when it can be confirmed, and remove this note.
Who invested
All of Boltz's existing investors put in more: Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. New investors include Greycroft, F-Prime Capital, Hummingbird and Benchling, the life sciences software company, alongside others the post does not name. No valuation was given.
From research group to company
Boltz started in 2025 as a small group of MIT researchers and now employs 40 people. It is organised as a public benefit corporation, Boltz PBC. It released its first proprietary models, BoltzMol-1 and BoltzProt-1, in June, and launched Boltz Lab, a platform for scientists, in January, when thousands signed up in the first weeks. It also offers a Boltz API for teams that want to call the models from their own software.
The company says it has partnerships with six of the world's 20 largest pharmaceutical companies, among them Pfizer, GSK, Takeda and Bristol Myers Squibb; its news page lists an agreement with Bristol Myers Squibb dated 21 October. Molecular token usage among paying customers has grown 50-fold since June, according to the post. These are the company's own figures.
"Our goal is to put better molecular design tools in the hands of all scientists developing the medicines of tomorrow," the Boltz team wrote.
What the money is for
Boltz plans to invest more in computing capacity and data, meet growing demand from its partners and grow its team.
What it means for research software buyers
Structure prediction and molecular design have moved quickly from academic tools to commercial platforms. For research and development leaders, Boltz offers a mix that buyers in this field increasingly ask for: open research roots, proprietary models on top and an API that fits into existing data platforms. The investment from Benchling, whose software many laboratories already use to record experiments, suggests closer links between the two may follow.
Teams evaluating Boltz or its rivals should ask how models are validated against experimental data in their own therapeutic area, what happens to proprietary molecules and assay data sent to a hosted platform, and whether models can be run inside their own cloud for sensitive programmes. Licence terms for open models and proprietary ones often differ, so check which applies before building a pipeline on either.
Sources
- Boltz: Announcing our Series A, 18 November 2026
- Boltz news, 18 November 2026
Categories & features
- United States
- Machine Learning
- Venture Capital
TrustList Weekly
The week in software and IT, in one email
The news that matters to buyers, new rankings and our own research. Every Thursday, free, and easy to leave.
You may be interested in
The start-up lists Stanford professor Yejin Choi and co-chief executive Prithviraj Ammanabrolu on its team; it has not published the investors or the stage itself.
The San Francisco startup, from Y Combinator's Spring 2026 batch, builds patient-level datasets from scattered hospital records and works in the US, Brazil, India and Argentina.
The young AI lab says it spent a year building new GPU primitives to cut how much data models need. Index and Lux co-lead, nine months after a $180 million seed.
a16z and F-Prime lead the Series A, with seed leads Obvious Ventures and E14 Fund following on. Eka claims 1,500 picks an hour, about two and a half times a human baseline.
B Capital and Kindred Ventures lead the round for the San Francisco company founded this year by former leads of NVIDIA's GR00T research; its Dream-1 model drives robot arms costing $2,000 to $10,000.
Vertex Ventures SEA & India led the Series B, with Hitachi Ventures joining. Total funding reaches $52.5 million after annual recurring revenue grew eightfold in six quarters.
Accel led the round at a $15.75 billion post-money valuation, five months after Modal's Series C. Its Sandboxes product alone runs at $300 million a year, and a London office has opened.
More on TrustList
Everything here links back to the same verified catalogue. Pick your next stop.
- More United StatesThe ranking for this subject
- CompaniesAgencies, consultancies and IT service providers, ranked by verified reviews.
- ProductsSoftware and SaaS with pricing, features, integrations and alternatives.
- AwardsAnnual recognition decided by verified reviews and an independent jury.
- LaunchesNew products and releases, voted up by the community every day.
- AI ModelsBenchmark scores and community ratings for every major model.
- RequestsBuyers describe what they need; vendors respond directly.
- PeopleReviewers, authors and makers with public profiles.
- ComparePut up to four listings side by side before you shortlist.